Introduction
The effectiveness of B cell-depleting antibodies as treatment in multiple sclerosis (MS) suggests that B cells play a central role in CNS myelin-directed autoimmunity (1) (2) (3) (4) (5) (6) . B cell repertoires in the periphery and CNS are closely linked in MS and other CNS autoimmune diseases, such as neuromyelitis optica, suggesting that disease-relevant B cell networks interact on both sides of the blood-brain barrier (7) (8) (9) (10) (11) . Multiple features of intrathecal B cells, such as the presence of memory B cells, short-lived plasmablasts (12) , and plasmablasts and plasma cells sharing the same B cell receptors (13) , and the accumulation of somatic hypermutations (SHM) in Ig genes, support the participation of B cells in the CNS in antigen-directed immunity. Compared with peripheral blood (PB) or immune organs, B cell receptor diversity in cerebrospinal fluid (CSF) is generally limited, suggesting selective recruitment and/or survival of B cell populations in the MS CNS (8, 10, 14) .
Clonal IgG (oligoclonal bands [OCBs] ) is present in the CSF of over 95% of patients with MS. The presence and long-term persistence of OCBs indicate ongoing local production of IgG in the CNS, either by resident long-lived plasma cells or by antibody-secreting cells that continuously mature from an existing pool of memory B cells. Anti-CD20 therapy with rituximab reduces B cell numbers in CSF without eliminating OCBs (15) ; thus, intrathecal production of clonal IgG is largely a function of CD20 -, long-lived plasma cells in CNS survival niches. Inflammatory infiltrates with lymphoid follicle-like structures are present in the meninges of patients with secondary progressive MS and are quite likely also present during the earlier relapsing phase of MS (16) (17) (18) ; such ectopic lymphoid tissues could support germinal center (GC) activity (19) , plasma cell maturation, and survival. Interestingly, however, natalizumab, an anti-VLA4 antibody that limits lymphocyte transmigration across the blood-brain barrier and effectively decreases MS disease activity reduces intrathecal IgG production at least in some patients (20) (21) (22) , which may suggest that OCB production also partially relies on peripheral stimuli.
Here, we studied the composition of the intrathecal and PB B cell compartments and performed Ig heavy chain variable region (Ig-VH) immune repertoire sequencing (Ig-RepSeq) to understand clonal relationships between B cell subsets on both sides of the blood-brain barrier in untreated MS patients.
A role of B cells in multiple sclerosis (MS) is well established, but there is limited understanding of their involvement during active disease. Here, we examined cerebrospinal fluid (CSF) and peripheral blood (PB) B cells in treatment-naive patients with MS or high-risk clinically isolated syndrome. Using flow cytometry, we found increased CSF lymphocytes with a disproportionate increase of B cells compared with T cells in patients with gadolinium-enhancing (Gd + ) lesions on brain MRI. Ig gene heavy chain variable region (Ig-VH) repertoire sequencing of CSF and PB B cells revealed clonal relationships between intrathecal and peripheral B cell populations, which could be consistent with migration of B cells to and activation in the CNS in active MS. In addition, we found evidence for bystander immigration of B cells from the periphery, which could be supported by a CXCL13 gradient between CSF and blood. Understanding what triggers B cells to migrate and home to the CNS may ultimately aid in the rational selection of therapeutic strategies to limit progression in MS.
Results
Clinical findings. Characteristics of patients in our study are summarized in Table 1 . The expanded disability status score (EDSS) was significantly higher in patients with Gd-enhancing (Gd + ) lesions on brain MRI (2.6 ± 0.3 SD) compared with patients without Gd enhancement (Gd -) (1.4 ± 0.3 SD; P = 0.009) ( Table 2) . Age, OCB, and IgG index were not different between Gd + and Gd -patient groups; CSFIgG levels were marginally higher in Gd + patients versus Gd -patients. Among Gd -patients, there were significantly more patients with a clinically isolated syndrome (CIS) versus a relapsing-remitting MS (RRMS) diagnosis (Table 2) ; however, virtually all patients with CIS in this study had OCB in their CSF, placing them in a high-risk category for clinically definite MS (23). Figure  1A ) but not T cells ( Figure 1B ). In keeping with an increase of absolute numbers of CSF lymphocytes during an inflammatory state, numbers of B and T cells per ml were increased in CSF of Gd + patients versus Gd -patients ( Figure 1 , C and D). To understand whether B and T cells were equally increased in Gd + CSF, we calculated the B/T cell ratio ( Figure 1E) Figure 2 , A and B), providing independent validation of previously published data (25) . The proportion of CD19 + B cells among lymphocytes was significantly lower in CSF than in PB ( Figure 2C ). The proportion of CD19 + CD27 -IgD + naive B cells was lower in CSF ( Figure 2D Table 1 for more information on the patients analyzed. Data are shown as scatter plots with mean ± 95% CI. Comparisons were made using an unpaired t test (GraphPad Prism); **P < 0.01, ****P < 0.0001. In accordance with a previous report by others (12) , our findings demonstrate that the CSF B cell pool is composed primarily of memory and differentiated B cells capable of providing antigen-specific antigen-presenting cell-mediated (APC-mediated) and antibody-mediated immune functionality.
PCs are increased in CSF of patients with Gd + MRI. Given the overall increased numbers of memory and CD27 hi B cells in MS CSF ( Figure 2 ) and a disproportionate increase in B cells in Gd + CSF (Figure 1 ), we sought to determine whether there is a balanced increase in all B cell subsets during active MS evidenced by a Gd + MRI. The absolute number of cells per ml was only significantly increased in SM and CD27 hi subsets ( .8% ± 14.2% in PB versus 11.5% ± 7.6% in CSF); USM are slightly increased (E, 19.1% ± 11.7% in PB versus 22.8% ± 10.4% in CSF); DN are increased (F, 4.0% ± 2.5% in PB versus 7.7% ± 7.3% in CSF); and SM are increased 2.5-fold (G, 18% ± 7.5% in PB versus 45.9% ± 11.8% in CSF). Most significantly, the percentage of CD27 hi B cells was increased 34-fold in CSF (H, 0.2% ± 0.2% in PB versus 7.6% ± 7.9% in CSF). Refer to Supplemental Table 1 for more information on the patients analyzed. Data are shown as scatter plots with mean ± 95% CI. Comparisons were made using paired t tests; ***P < 0.01, ****P < 0.0001.
relationships between CSF B cell subsets and their PB counterparts. To address this question, we performed Ig-RepSeq on CSF and PB samples (Table 1) . PB subsets (naive, USM, DN, SM, CD27 hi ) were sequenced from 11 patients. Matched bulk-sorted CSF B cells (i.e., all subsets sorted together in the same tube) were sequenced from 3 of these 11 patients (51113a, 51314a, and 51814a), CSF B cells sorted as 4 subsets (naive, USM, DN, SM/CD27 hi combined) from 2 of 11 patients (56414a and 56514a), and CSF B cell subsets sorted as 5 separate subsets (naive, USM, DN, SM, CD27 hi ) from 6 of 11 patients (56914a, 57114a, 57414a, 57514a, 57714a, and 64215a). Using IGHV gene-specific forward primers and IgM or IgG constant region reverse primers (Table 3) , extensive IgM/G-VH cDNA libraries were generated and then sequenced using an IonTorrent PGM sequencer (Supplemental Table  2 ). In total, we generated and analyzed nearly 1.3 × 10 7 Ig-VH sequences. In general, next-generation sequencing technologies are error-prone (26) , which, in the case of Ig-VH repertoire sequencing, can lead to overestimation of SHM and Ig repertoire diversity. We applied our bioinformatics pipeline to first discard nonproductive (i.e., incorrect reading frame) sequencing reads. In a next step, we determined IGHV/IGHJ usage, H-CDR3 amino acid sequence, and the number of mutations away from the closest IGHV germline segment (SHM) for each sequence; this information, along with the B cell subset origin (i.e., naive, SM, USM, DN, CD27 hi ) and isotype (i.e., IgG, IgM), was used to annotate each productive Ig-VH read. SHM profiles generated for each PB subset largely replicated what would be expected biologically (Figure 4) , i.e., low SHM counts in naive B cell IgM-VH and increasing SHM in more mature B cells, with the highest number of SHMs being present in IgG-expressing CD27 hi B cells ( Figure 4A ). USM B cells had also accumulated some level of SHM, despite not having undergone class-switch recombination ( Figure 4B ). SHM profiles of CSF B cell subsets were reflective of the limited diversity found in this compartment (Figure 4, C and D) . hi B cells. Shown are scatter plots with each point representing findings from a single patient, and all data are shown as mean ± 95% CI, except for those in E, where the ratio of means is shown and therefore no error bars can be calculated. Refer to Supplemental Table 1 for more information on the patients analyzed in A-E. Comparisons were made using an unpaired t test; *P < 0.05, **P < 0.01.
To identify clonal overlap between CSF and PB B cells based on Ig-RepSeq data, we used a previously published distance-metric clustering approach (Hamming distance; see Methods), placing all Ig-VH with related H-CDR3 and identical IGHV and IGHJ usage in clusters of clonally related Ig-VH (Ig-VH clusters). This approach is insensitive to possible sequencing errors in Ig-VH reads, as clonally related Ig-VH are combined in their appropriate cluster irrespective of whether SHM or sequencing errors altered the Ig-VH. Clonal relationships were identified between different CSF and PB B cell subsets in each patient. Figure 5 shows overviews of clonal relationships between CSF and PB B cell subsets for all patients from which Ig-RepSeq data was available ( Figure 5A ). Supplemental Table 3 lists the frequencies of clonal connections among each B cell subpopulation shown in Figure 4 . Supplemental Table 4 lists the characteristics of CSF Ig-VH clusters, whether they were exclusively found in CSF, or to which PB B cell subsets clonal relationships were identified. IGHV usage distribution per analyzed patient and sample/subset is shown in Supplemental Figure 2 .
Increased CSF B cells were correlated with overall number of CSF Ig-VH clusters (R 2 = 0.633, P = 0.0034) ( Figure 5B) and with CSF "restricted" Ig-VH clusters (i.e., clusters for which no related sequences were found in the matched PB sample) (R 2 = 0.6675, P = 0.021) ( Figure 5C ) and partially correlated with the proportion of PB Ig-VH clusters with clonal relationships to the CSF (R 2 = 0.4044, P = 0.0355) ( Figure  5D ). These findings suggest that influx and intrathecal expansion of B cells occur during active MS.
We found clonally related Ig-VH expressed by CSF CD27 hi and peripheral B cell subsets in all patients from which CD27 hi B cells could be sorted (all were Gd + ) ( Figure 6 ), suggesting that peripherally antigen-stimulated B cells may have migrated to the CSF compartment where they became activated to further mature into antibody-secreting CD27 hi B cells. In addition, we identified clusters of related Ig-VH that were exclusively expressed by CSF B cells, including some found in CSF SM and CD27
hi B cells, which may point toward intrathecal activation without a peripheral contribution ( Figure 6 ). In 6 Gd + patients, we identified Ig-VH clusters containing IgM-VH and IgG-VH derived from CSF B cells, possibly indicating intrathecal Ig class-switch recombination (Supplemental Table 3 ).
Interestingly, we also found substantial clonal overlap between CSF USM B cells and PB USM, SM, and DN B cells but only a limited clonal relatedness of CSF USM to CSF CD27 hi or SM B cells ( Figure  6 ); SHM profiles of USM B cells were most closely related to SHM profiles of IgM-expressing PC and SM B cells ( Figure 4B ). We were able to sort naive B cells from CSF and obtain IgM-VH sequences from 4 patients; as was the case for USM B cells, clusters containing CSF naive B cells were almost exclusively clonally connected to the periphery and did not include post-GC CSF B cells, potentially suggesting bystander influx without further intrathecal stimulation ( Figure 6 and Supplemental Figure 3) . The presence of related Ig-VH expressed by naive B cells in CSF and by peripheral B cells also supports homeostatic proliferation (i.e., nonantigen-driven clonal expansion) of naive B cells.
B cell CXCR5 and CSF CXCL13 as possible drivers of B cell migration to the CNS during active MS. Finally, we explored the possibility that CXCR5 on B cells and CXCL13 in CSF might be involved in B cell recruitment to CSF during active MS by measuring CXCL13 levels in CSF obtained usually on the same day of the brain MRI. In alignment with the finding that increased B cell migration to the CSF occurs in active MS, we 
Forward primers
General design 5′-trP1 adaptor-IGHV1- 7-3′  VH1  5′-CCTCTCTATGGGCAGTCGGTGAT-GAARRTYTCCTGCAAGGYWTC-3′  VH2  5′-CCTCTCTATGGGCAGTCGGTGAT-CACRCTGACCTGCACCKTCTC-3′  VH3  5′-CCTCTCTATGGGCAGTCGGTGAT-KARACTCTCCTGTRCAGCCTB-3′  VH4  5′-CCTCTCTATGGGCAGTCGGTGAT-GTCCCTCACCTGCRCTGTCTM-3′  VH5  5′-CCTCTCTATGGGCAGTCGGTGAT-GARGATCTCCTGTAAGGGTTC-3′  VH6  5′-CCTCTCTATGGGCAGTCGGTGAT-CTCACTCACCTGTGCCATCTC-3′  VH7 5′-CCTCTCTATGGGCAGTCGGTGAT-GAAGGTTTCCTGCAAGGCTTC-3′
Reverse primers
General design 5′-adaptor-barcode+GAT key-IgG/M gene-specific sequence-3′ IgG 5′-CCATCTCATCCCTGCGTGTCTCCGACTCAG-barcode-GAT-GGGAAGACSGATGGGCCCTTGGTGG-3′ IgM 5′-CCATCTCATCCCTGCGTGTCTCCGACTCAG-barcode-GAT-GGAGTCGGGAAGGAAGTCCTGTGCGAG-3′
Downloaded from http://insight.jci.org on November 24, 2017. https://doi.org/10.1172/jci.insight.92724 found levels of CXCL13 in CSF of Gd + patients (n = 5) that were similar to plasma CXCL13 levels, while no CXCL13 was detectable in Gd -CSF (n = 5) using a commercial ELISA assay ( Figure 7A ). The receptor for CXCL13, i.e., CXCR5, was identified on most B cells ( Figure 7B) ; however, significantly fewer CSF and PB CD27 hi B cells expressed CXCR5. To assess whether the presence of CSF CXCL13 in Gd + CSF was merely due to increased passive exchange of soluble factors from the periphery across a compromised blood-brain barrier, we also measured other chemokines and cytokines of similar or higher molecular weight as CXCL13 (10.7 kDa), i.e., CXCL12 (8.5 kDa), BAFF (31.2 kDa), and APRIL (27.4 kDa) (Figure 7, C-E) . We found that CXCL12 and BAFF levels were lower in CSF than PB independent of Gd enhancement, while APRIL may even be slightly, though not statistically significantly, increased in Gd -CSF. Overall, these data suggest that CXCL13 in Gd + CSF is produced locally in the CSF or CNS compartments and may be involved in the recruitment of diverse populations of CXCR5-expressing B cells during active MS, except for CD27 hi B cells.
Discussion
We performed comprehensive analyses of CSF and peripheral B cells in patients with a new diagnosis of RRMS or high-risk CIS who had never been treated with disease-modifying therapy for MS. Most patients (34 of 39) had OCBs in their CSF, suggesting a preestablished intrathecal plasma cell repertoire as potential evidence for immune activation and CNS infiltration that may have occurred prior to CSF sampling. With regards to the CSF lymphocyte composition, we confirmed that T lymphocytes are much more prevalent than B cells in CSF of MS patients, that absolute numbers of both B and T cells are increased in active MS (27) , and that the CSF is enriched with memory B cells (28) . In patients with Gd + lesions on brain MRI, we found a disproportionate increase in B cell numbers compared with T cells, suggesting that B cell immigration and/or activation is associated with active MS. We found increased CD27 hi B cells in CSF, confirming earlier reports that intrathecal plasma cells are associated with active CNS inflammation in MS (12, 29) and suggesting antigen-driven B cell activation. This is interesting considering that plasma cells are antibody-secreting cells and that the pathological involvement of antibodies in MS remains poorly understood (30) . Antibody-secreting cells are clonally expanded in the CSF where they participate in the production of clonal IgG (i.e., OCBs) (7, 31, 32) ; their presence in the CSFs studied here and their apparent association with MS disease activity further support antigen-driven and possibly antibody-mediated mechanisms as playing a key role in MS immune pathology.
We previously showed that clonally related B cells are present in CSF and PB of MS patients (7, 8, 10) . Here, we were interested in the clonal relationships between B cell subsets in untreated MS CSF and PB. In B cells, random somatic recombination of Ig germline genes (IGHV, IGHD, IGHJ), SHM, and Ig class-switch recombination shape the highly diverse B cell repertoire and generate readily identifiable and specific molecular signatures that can be exploited for the identification of clonally related B cells in spatially separated compartments and/or different B cell subsets. We applied flow cytometry in combination with Ig-RepSeq to identify clonally related B cells in CSF or PB. Our results suggest that during episodes of disease activity, diverse populations migrate to and/or are stimulated within the CNS/CSF compartment.
Unresolved questions are how MS relapses are triggered and whether antigen-specific or nonspecific restimulation is required for relapsing disease activity. Our finding of a preexisting network of potentially disease-driving immune cells on both sides of the blood-brain barrier could explain how relapsing immune activity is facilitated, such as when patients experience relapses during systemic infection (33, 34) . Indeed, we found clonally related CD27
hi PCs in PB and CSF that were also related to Ig class-switched-memory B cells in the same compartments. Given that CD27
hi PCs are likely restricted to their compartment (as evidenced by their low CXCR5 expression), and the persistence of memory B cells in MS CSF and CNS in general, parallel maturation of preexisting SM B cells on both sides of the blood-brain barrier may have occurred following a peripheral immune activating event. The presence of clonal relationships between memory B cells and CD27 hi plasma cells in the CSF and CSF Ig-VH clusters containing related IgM-VH and IgG-VH also support local B cell activation and subsequent maturation and class-switch recombination.
Clearly, the MS disease process is complex, with multiple mechanisms contributing to relapsing activity. The efficacy of natalizumab in suppressing MS relapses supports common thinking that peripheral activation, transmigration, and intrathecal maturation of SM B cells to CD27
hi PCs also contributes to MS disease activity (35) . Our finding of a positive correlation between bicompartmental B cell clusters and the proportion of CSF CD19 + B cells suggests that peripherally activated B cells may be directly contributing to intrathecal inflammation and B cell activation in MS. Together with previous evidence of intrathecal IgMand IgG-VH SHM (10, (36) (37) (38) , our findings add to a model (Figure 8) of B cell activation that may originate in the periphery, continue in the CNS compartment, partially involve preexisting intrathecal memory B cells, and may also attract antigen nonspecific subsets to the CNS compartment.
Interestingly, while we did find naive CSF B cells with clonally related counterparts in the periphery, naive B cells do not seem to become stimulated intrathecally to mature to memory B cells. Thus, GC functionality may only be partially represented intrathecally, providing support for class-switch recombination, SHM (19) , and plasma cell maturation but not for further differentiation or survival of naive B cells. The latter point is also supported by the fact that, contrary to PB, naive B cells are among the least abundant B cells in CSF. Ig non-class-switched IgD-expressing memory B cells (USM) have been described in MS CSF (25) . Here, we found that CSF USM B cells are clonally related to a variety of peripheral B cell subsets, including IgG-expressing SM and CD27 hi B cells. CD19 (40) by generating diverse low-affinity IgM. Additional work will be necessary to understand the involvement of IgD-expressing memory B cell subsets in MS.
We also studied CXCL13 and CXCR5 in a small subcohort of patients and found detectable levels of CXCL13 only in CSF of patients with Gd + lesions, which is consistent with prior reports of increased CXCL13 during MS relapses (41) . Thus, a B cell-attracting CSF environment appears to be generated during phases of disease activity, and an inverse CXCL13 gradient (i.e., higher in plasma, absent in CSF), as observed in Gd -patients, might promote B cell egress from the CNS during periods of remission. CSF CXCL13 may derive from actively demyelinating lesions (42) or from meningeal ectopic lymphoid sites (43) . Only a minority of CD27 hi B cells in PB and CSF expressed CXCR5, the receptor for CXCL13, while the majority of other CSF and PB B cell subsets were CXCR5 + . Thus, the CXCL13/CXCR5 interaction may be generally involved in B cell recruitment to the CNS; however, it is specifically not involved in the recruitment of CD27 hi B cells. Accordingly, CSF PCs more likely matured within the CNS/CSF compartment from plasma cell progenitors that were either present in this compartment or had newly entered the CNS during the phase of disease activity. We found the highest levels of CXCR5 on naive and USM B cells. Interestingly, we found USM and naive B cells in CSF with clonally related counterparts in the periphery and, particularly in the case of naive B cells, a striking absence of intra-CSF clonal relatedness to post-GC B cells. This observation could reflect nonspecific bystander recruitment of CXCR5-expressing B cells along a CXCL13 gradient and supports the presence of homeostatically proliferated naive B cells as previously described (44) .
In summary, our data in treatment-naive MS patients suggest substantial influx and activation of diverse B cell populations during episodes of MS disease activity that may feed into ectopic lymphoid compartments, as described in patients with progressive MS (16, 18) . The presence of OCB and CSF B cell repertoires, which likely existed prior to the disease activity period observed in our study, suggests long-term survival of B cells in the CNS compartment, which may facilitate peripherally triggered relapsing activity from within. Following completion of phase III trials (5, 6), anti-CD20 therapy has now been approved for the treatment of relapsing and progressive MS in the US. However, important questions remain regarding CD20-targeted B cell-depleting therapy: when to start treatment to not only limit disease activity but to most effectively delay or even prevent secondary progression? Should anti-CD20 therapy be used as second-line therapy in patients with ongoing disease activity under another disease-modifying therapy, or should it be used as first-line therapy? Once established in the intrathecal (i.e., leptomeningeal or CNS parenchymal), compartment B cells may be less effectively targeted by peripher-CSF or PB subsets (patient 56414). For comprehensive information on clonal relationships between CSF B cells and other subsets see Supplemental ally acting B cell-depleting therapies (45) . While anti-CD20 antibodies appear to be moderately effective in progressive MS (6, 46) , onset of secondary progression may not be prevented if treatment is started too late (47) . Therefore, it may be desirable to limit B cell influx into the CNS as early and effectively as possible to most successfully limit immune mechanisms that support MS progression.
Methods
Patients and samples. CSF and PB were sampled from a total of 39 patients recruited at the UCSF MS Center. All patients were treatment naive (i.e., no glucocorticoids or disease-modifying MS therapy at any time prior to lumbar puncture [LP] and MRI), sought medical care for a possible new diagnosis of MS, and met clinical and radiographic diagnostic criteria for RRMS or CIS. PB was obtained by venipuncture. CSF was obtained by standard LP; the first 1-3 ml CSF were discarded and then CSF was obtained for clinical purposes. On average, 11.2 ml (±3.35 ml, SD) of CSF were obtained for research studies at the end of the LP procedure. MRI imaging of the brain and spinal cord with and without Gd was obtained for each patient within ±1 day of their LP; lesion counts (T1 Gd + or T2) or volumes were not determined for this study. Flow cytometry analysis and sorting. Peripheral mononuclear blood cells (PBMCs) were isolated using a Ficoll gradient, red blood cell lysis, and washing with phosphate-buffered saline (PBS) and 1% bovine serum albumin. PBMCs (5 × 10 . In combination, CXCR5 is present on more PBMCs than CSF CD19 + B cells and only expressed on a minority of PBMCs and CSF CD27 hi plasmablasts/plasma cells. There was no significant difference between CXCL12 (C), BAFF (D), and APRIL (E) in CSF from Gd + or Gd -patients. Overall CXCL12 and BAFF levels were higher in plasma than in CSF. Cytokine/chemokine concentrations were determined in CSF and plasma samples from Gd + and Gd -patients by ELISA (n = 5 per group; see Table 1 ). Data are shown as scatter plots with mean ± 95% CI. Comparisons were made using unpaired or paired t tests; *P < 0.05, **P < 0.01, ****P < 0. were analyzed from all patients in this study and sorted and subjected to Ig-RepSeq from 11 patients (Table 1) . CSF lymphocytes from all patients were analyzed by flow cytometry and either bulk sorted (n = 3: 51113a, 51314a, and 51814a) or when possible sorted as 4 (naive, USM, DN, SM/CD27 hi combined: n = 2, 56414a and 56514a) or 5 separate subsets (n = 6: 56914a, 57114a, 57414a, 57514a, 57714a, and 64215a).
Ig-RepSeq. Total RNA was extracted from sorted B cell subsets (RNeasy Micro Kit, Qiagen) and reverse transcribed (iScript cDNA Synthesis Kit, Bio-Rad). PB and CSF cDNA was used for IgM-VH and IgG-VH amplification by PCR (Advantage 2 PCR Kit, Clontech) using a pool of custom-designed IGHV1-7 family forward primers and IgG-or IgM-specific reverse primers with IonXpress barcodes to uniquely tag each subset/isotype prior to library prep (Table 2) . PB samples were subjected to 30-35 cycles of PCR, and CSF subsets were amplified 35-50 cycles in increments of 5 cycles until product was detected by agarose gel. PCR-amplified product was purified using a 1.5% agarose gel with Sybr Safe and extracted (MiniElute Kit, Qiagen). Gel-purified DNA was quantified (High Sensitivity DNA Kit and Bioanalyzer, Agilent Biotechnologies) and then diluted to 13.5-16 pM to create an equimolar DNA library. The DNA library underwent emulsion PCR (Ion OneTouch2 Kit, Life Technologies) to bind and clonally expand DNA fragments onto IonSphere beads (ISP) for sequencing. Enriched ISPs were quality control checked using a Qubit Fluorometer and sequenced on the Ion PGM System (Life Technologies) using 318 v2 chips. Sequence files are available in fastq format at NCBI (BioProject accession PRJNA397295)
CSF and plasma cytokine/chemokine ELISAs. Concentrations of CXCL13, CXCL12, and BAFF were (Figures 5 and 6 ). These immune mechanisms support MS disease activity (evidenced by Gd + MRI lesions; example from patient 57514) and lead to increased production of CXCL13 (D), which, in turn, also attracts CD27 -B cells to the CNS/CSF compartment (E). These CD27 -B cells may not have been involved in the initial peripheral immune triggering event; rather, their migration to the CNS could be a nonspecific event. Activated CD27 + B cells, once in the CNS, may further mature to antibody-secreting plasmablasts/plasma cells and may home to ectopic lymphoid sites (F). We found no evidence for CD27 -IgD + B cells maturing to antigen-specific CD27 + B cell subset; the fate of naive B cells in CSF remains unknown (G). It is important to note that several steps described in this model remain hypothetical and subject of future research. measured in plasma and CSF using commercially available ELISA kits from R&D Systems, and concentrations of APRIL were determined using ELISA kits from eBioscience. All dilutions and sample measurements were performed according to the manufacturer's instructions. Optical density of each plate was read at 450 nm within 30 minutes using a microplate reader. The quantitative results were then statistically evaluated using a nonparametric t test (Graphpad Prism).
MRI acquisition and analysis. MRI scans were acquired on a 3T Siemens scanner following a standardized protocol that included 3D T1-weighted magnetization-prepared Gradient echo images (T1-MPRAGE), 3D fluid-attenuated inversion recovery (FLAIR), and T2/PD images of the brain and T2-weighted and short tau inversion recovery (STIR) images of the spinal cord. Brain MPRAGE and T1-weighted spinal cord images were acquired after administration of gadopentetate dimeglumine. Readings were performed blinded to the clinical and immunological data.
Statistics and immune repertoire analysis. Statistical analyses were performed using GraphPad Prism. A 2-tailed t test was used for linear measures and Fisher's exact test for group comparisons; P values of less than 0.05 were considered significant. P values of less than 0.05 were considered statistically significant. Fastq sequence files were generated based on raw sequencing output files (BAM format) retrieved from the IonTorrent PGM Sequencer. For all reads, IGHV and IGHJ usage, H-CDR3 amino acid sequence, and numbers of SHM along the IGHV portion of each Ig-VH sequence were determined using a custom pipeline incorporating sequence alignments and MiXCR (48) (Note that the compiled bioinformatics pipeline is available for download; https://github.com/swuecho/Immune-repertoire-network). Clonally related IgM/G-VH sequences were clustered based on H-CDR3 similarity (Hamming distance = 2; ref. 49 ) and usage of the same IGHV and IGHJ germline segments. Simplified views displaying the overall number of clusters per B cell subset and numbers of clonal connections (i.e., relationships) between subsets were visualized in Cytoscape version 3.3.0 (50). The goal of our analysis was to obtain information regarding the presence of clonally related Ig-VH derived from different B cell subsets in CSF and/or PB.
Study approval. All investigations were IRB approved (UCSF Committee on Human Research), and all patients provided written informed consent. This study was conducted in accordance with the Declaration of Helsinki.
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